| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
Notopterol has been reported to target various pathways. Its anti-inflammatory effects are thought to be mediated through the inhibition of pro-inflammatory mediators. Its analgesic effects may involve modulation of pain pathways. It has also been studied for its effects on the central nervous system, suggesting it may interact with neurotransmitter systems.
|
|---|---|
| ln Vitro |
In a dose-dependent manner, notopterol (5, 10, 20, 40, and 60 μM; for 48 hours) induces apoptosis [1]. In a concentration-dependent way, notopterol (10, 20, 40, 60, and 80 μM; 24-120 hours) suppresses the growth of HL-60 cells [1]. In HL-60 cells, notopterol (5, 10, 20, and 40 μM) causes cyclin-related G0/G1 arrest during a 48-hour period [1]. After 48 hours of treatment, Bax expression was elevated while Bcl-2 and Mcl-1 expression was decreased in HL-60 cells treated with notopterol (5, 10, 20, and 40 μM). Furthermore, Notopterol facilitates the cleavage of PARP, caspase 3, and caspase 9 [1].
In vitro, Notopterol has been shown to inhibit the production of inflammatory mediators in cell-based assays. It has also demonstrated antioxidant activity. Its effects on neuronal cells have been studied. Its activity is characterized by its ability to modulate inflammatory and oxidative stress pathways. |
| ln Vivo |
In vivo, Notopterol has demonstrated anti-inflammatory and analgesic effects in animal models. It has been studied for its potential to treat inflammatory conditions and pain. Its effects on the central nervous system have also been investigated.
|
| Enzyme Assay |
In vitro enzyme/receptor binding studies for Notopterol are not detailed in the provided sources. Its anti-inflammatory activity is likely assessed by measuring its effects on the production of inflammatory mediators in cell culture.
|
| Cell Assay |
In vitro cellular assays for Notopterol are used to study its effects on cells. In immune cells, its ability to inhibit the production of pro-inflammatory cytokines is measured. In neuronal cells, its effects on cell viability and signaling are studied.
|
| Animal Protocol |
In vivo animal studies for Notopterol are conducted in models of inflammation and pain. Animals are treated with the compound, and the reduction in inflammation or pain response is measured.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Notopterol are not detailed in the provided sources. It has a molecular weight of 270.28 g/mol and a formula of C16H14O4.
|
| Toxicity/Toxicokinetics |
Notopterol is a natural compound and is generally considered to have a low toxicity profile. Specific toxicity data are not detailed in the provided sources.
|
| References | |
| Additional Infomation |
Notopertrol is a furanocoumarin. It has been reported that notopertrol exists in Hansenula foetida and Hansenula vegetans, and relevant data are available for reference.
Notopterol is a naturally occurring furanocoumarin with anti-inflammatory and analgesic properties. Its CAS number is 88206-46-6. It is a research compound used to study the pharmacology of natural products. It is not an approved drug. |
| Molecular Formula |
C21H22O5
|
|---|---|
| Molecular Weight |
354.3964
|
| Exact Mass |
354.146
|
| CAS # |
88206-46-6
|
| PubChem CID |
5320227
|
| Appearance |
White to off-white solid powder
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
546.7±50.0 °C at 760 mmHg
|
| Flash Point |
284.4±30.1 °C
|
| Vapour Pressure |
0.0±1.5 mmHg at 25°C
|
| Index of Refraction |
1.599
|
| LogP |
4.25
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
26
|
| Complexity |
602
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC(=CC(C/C(=C/COC1=C2C=CC(=O)OC2=CC3=C1C=CO3)/C)O)C
|
| InChi Key |
BKIACVAZUKISOR-MKMNVTDBSA-N
|
| InChi Code |
InChI=1S/C21H22O5/c1-13(2)10-15(22)11-14(3)6-8-25-21-16-4-5-20(23)26-19(16)12-18-17(21)7-9-24-18/h4-7,9-10,12,15,22H,8,11H2,1-3H3/b14-6+
|
| Chemical Name |
4-[(2E)-5-hydroxy-3,7-dimethylocta-2,6-dienoxy]furo[3,2-g]chromen-7-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~282.17 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 2.5 mg/mL (7.05 mM) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 2.5 mg/mL (7.05 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (7.05 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.8217 mL | 14.1084 mL | 28.2167 mL | |
| 5 mM | 0.5643 mL | 2.8217 mL | 5.6433 mL | |
| 10 mM | 0.2822 mL | 1.4108 mL | 2.8217 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
